Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
Wen Li, David C. Newitt, Jessica Gibbs, Lisa J. Wilmes, Ella F. Jones, Vignesh A. Arasu, Fredrik Strand, Natsuko Onishi, Alex Anh Tu Nguyen, John Kornak, Bonnie N. Joe, Elissa R. Price, Haydee Ojeda-Fournier, Mohammad Eghtedari, Kathryn W. Zamora, Stefanie A. Woodard, Heidi Umphrey, Wanda Bernreuter, Michael Nelson, An Ly ChurchPatrick Bolan, Theresa Kuritza, Kathleen Ward, Kevin Morley, Dulcy Wolverton, Kelly Fountain, Dan Lopez-Paniagua, Lara Hardesty, Kathy Brandt, Elizabeth S. McDonald, Mark Rosen, Despina Kontos, Hiroyuki Abe, Deepa Sheth, Erin P. Crane, Charlotte Dillis, Pulin Sheth, Linda Hovanessian-Larsen, Dae Hee Bang, Bruce Porter, Karen Y. Oh, Neda Jafarian, Alina Tudorica, Bethany L. Niell, Jennifer Drukteinis, Mary S. Newell, Michael A. Cohen, Marina Giurescu, Elise Berman, Constance Lehman, Savannah C. Partridge, Kimberly A. Fitzpatrick, Marisa H. Borders, Wei T. Yang, Basak Dogan, Sally Goudreau, Thomas Chenevert, Christina Yau, Angela DeMichele, Don Berry, Laura J. Esserman, Nola M. Hylton
Dive into the research topics of 'Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL'. Together they form a unique fingerprint.